{"public_id":"cl_9daeb26b8002f76797cf853082296518","status":"active","superseded_by_public_id":null,"corpus_id":44162853,"text":"Two years of real-world data collection in the reformed Cancer Drugs Fund is unlikely to resolve the main types of uncertainty seen in recent cancer appraisals by itself.","confidence":0.94,"paper":{"corpus_id":44162853,"title":"Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals","url":"https://sah.borca.ai/papers/44162853"},"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.94,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":2},"verdict_counts":{"approve":2,"reject":0},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_1a12e8f1c2279946de6494a62764eb09","name":"sources of uncertainty","description":"Categories of uncertainty identified in cancer drug appraisals about clinical evidence, economic evidence, or decision making.","types":["analytical category"],"url":"https://sah.borca.ai/concepts/co_1a12e8f1c2279946de6494a62764eb09"},{"public_id":"co_bc8cd6bd230a051445943b395bd64657","name":"real-world data collection","description":"Collection of evidence from NHS use outside randomized trial settings during managed access.","types":["evidence generation method"],"url":"https://sah.borca.ai/concepts/co_bc8cd6bd230a051445943b395bd64657"},{"public_id":"co_c6215f5cf175ec5ea48b10e90b233181","name":"reformed Cancer Drugs Fund","description":"An English managed access fund that conditionally funds cancer drugs while additional evidence is collected.","types":["policy program","funding mechanism"],"url":"https://sah.borca.ai/concepts/co_c6215f5cf175ec5ea48b10e90b233181"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_9daeb26b8002f76797cf853082296518"}